Skip to main content
Back
Watch Compare

Karyopharm Therapeutics Inc.

Data quality: 100%
KPTI
Nasdaq Manufacturing Chemicals
$8.15
▲ $0.90 (12.41%)
Mkt Cap: 183.73 M
Price
$8.15
Mkt Cap
183.73 M
Day Range
$7.19 — $8.18
52-Week Range
$3.65 — $10.99
Volume
895,748
Open $7.22
50D / 200D Avg
$7.62
6.89% above
50D / 200D Avg
$6.27
29.96% above

Quick Summary

Key Takeaways

Revenue declined -8.66% annually over 5 years
Negative free cash flow of -75.37 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 9.23%
Capital efficient — spends only 0.00% of revenue on capex

Growth

Revenue Growth (5Y)
-8.66%
Below sector avg (1.82%)
Revenue (1Y)0.57%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC-972.43%
Net Margin-134.21%
Op. Margin-62.10%

Safety

Debt / Equity
N/A
Current Ratio1.03
Interest Coverage-1.98

Valuation

PE (TTM)
-0.94
Above sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.9 -1.5
P/B — 1.6
ROE % — -53.5
Net Margin % -134.2 -41.5
Rev Growth 5Y % -8.7 1.8
D/E — 0.3

ETFs Holding This Stock

BRUSX BRUSX
0.41% weight
BRSIX BRSIX
0.04% weight
DLHIX DLHIX
0.04% weight
DLHAX DLHAX
0.04% weight
DLRHX DLRHX
0.04% weight
BDSCX BDSCX
0.01% weight
BDSKX BDSKX
0.01% weight
BDSAX BDSAX
0.01% weight
BDSIX BDSIX
0.01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0.57% Revenue Growth (3Y) 0.01%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -8.66% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 146.07 M Net Income (TTM) -196.04 M
ROE N/A ROA -194.96%
Gross Margin N/A Operating Margin -62.10%
Net Margin -134.21% Free Cash Flow (TTM) -75.37 M
ROIC -972.43% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1.03
Interest Coverage -1.98 Asset Turnover 1.45
Working Capital 2.59 M Tangible Book Value -269.26 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.94 Forward P/E N/A
P/B Ratio N/A P/S Ratio 1.26
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -41.02%
Market Cap 183.73 M Enterprise Value 146.06 M
Per Share
EPS (Diluted TTM) -17.93 Revenue / Share 6.48
FCF / Share -3.34 OCF / Share -3.34
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.00% FCF Conversion 38.45%
SBC-Adj. FCF -89.70 M Growth Momentum 9.23

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 146.07 M 145.24 M 146.03 M 157.07 M 209.82 M
Net Income -196.04 M -76.42 M -143.10 M -165.29 M -124.09 M
EPS (Diluted) -17.93 -0.93 -1.25 -2.02 —
Gross Profit — — — — —
Operating Income -90.71 M -119.44 M -129.54 M -142.20 M -98.27 M
EBITDA — — — — —
R&D Expenses 125.62 M 143.23 M 138.75 M 148.66 M 160.84 M
SG&A Expenses 105.21 M 115.44 M 131.88 M 145.40 M 143.85 M
D&A — — — — —
Interest Expense 45.85 M 37.42 M 23.82 M 25.00 M 26.05 M
Income Tax 43,000.0 57,000.0 323,000.0 369,000.0 268,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 108.42 M 164.42 M 240.44 M 358.17 M 305.31 M
Total Liabilities 401.34 M 350.44 M 376.64 M 374.83 M 384.98 M
Shareholders' Equity -292.93 M -186.02 M -136.21 M -16.66 M -79.67 M
Total Debt — — — — 169.29 M
Cash & Equivalents 60.54 M 62.48 M 52.23 M 135.19 M 190.46 M
Current Assets 103.15 M 156.49 M 233.92 M 350.16 M 275.61 M
Current Liabilities 92.06 M 92.26 M 69.48 M 65.91 M 73.72 M